Mast Therapeutics, Inc. (MSTX)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
0.13-0.01 (-4.28%)
At close: 4:01 PM EDT
People also watch:
RNNIMUCPTXSPHSIMNP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.14
Prev Close0.13
Bid0.13 x 10000
Ask0.13 x 2200
Day's Range0.12 - 0.14
52wk Range0.10 - 0.71
1y Target EstN/A
Market Cap27.01M
P/E Ratio (ttm)-0.53
Beta-1.35
Volume23,151,235
Avg Vol (3m)7,398,912
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Investopedia4 days ago

    Mast Therapeutics Crash Led By Poor Results (MSTX)

    The company's shares have suffered in the wake of failed drug studies that forced it to cancel clinical development plans

  • TheStreet.com4 days ago

    5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid

    Here's a technical look at how to trade some of the most active stocks on the market right now.

  • PR Newswire5 days ago

    Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease

    While clearly not the outcome we wanted, we believe the insights and data from the largest placebo-controlled clinical trial ever completed in sickle cell disease will substantially advance the understanding of vaso-occlusive crisis and the still maturing clinical science necessary to support the development of new therapeutics for this debilitating disease," stated Brian M. Culley, the Company's Chief Executive Officer. "These analyses are limited to just top-line data, so in the coming weeks the Company intends to review the full data set from EPIC. In addition, we plan to perform an interim analysis of the ongoing heart failure trial of vepoloxamer.